Monday, January 9, 2017

Healio - Zepatier highly effective for inducing SVR in HCV patients with prior treatment failure

Zepatier highly effective for inducing SVR in HCV patients with prior treatment failure

Zepatier treatment for 12 weeks, with or without ribavirin, was highly effective for induction of sustained virologic response in patients infected with hepatitis C genotypes 1, 4 or 6, who failed prior peg-interferon and ribavirin treatments, according to the results of the C-EDGE Treatment Experienced trial. SVR12 was also achieved by patients with cirrhosis or a null response to previous treatment in this trial, and the treatment was generally well tolerated.

To evaluate the effectiveness of elbasvir/grazoprevir in treatment-experienced patients infected with HCV genotypes 1, 4 or 6, Paul Y. Kwo, MD, FACG, FAASLD, of the division of gastroenterology/hepatology in the department of medicine at Stanford University School of Medicine, Palo Alto, Calif., and colleagues performed an international multicenter, open-label phase 3 randomized controlled trial of the drug regimen in this difficult to treat patient population

Continue reading...

No comments:

Post a Comment